Literature DB >> 33403685

Commentary on Hill et al.: Breaking down barriers-increasing access to lifesaving opioid use disorder medications to save lives.

Michael S Toce1,2,3, Scott E Hadland4,5.   

Abstract

Entities:  

Keywords:  Buprenorphine; harm reduction; naloxone; opioid-use disorder; treatment; youths

Mesh：

Substances：

Year:  2021        PMID： 33403685      PMCID： PMC8131207          DOI： 10.1111/add.15375

Source DB:  PubMed          Journal:  Addiction        ISSN： 0965-2140            Impact factor:   7.256


× No keyword cloud information.
  19 in total

1.  Trends in Receipt of Buprenorphine and Naltrexone for Opioid Use Disorder Among Adolescents and Young Adults, 2001-2014.

Authors:  Scott E Hadland; J Frank Wharam; Mark A Schuster; Fang Zhang; Jeffrey H Samet; Marc R Larochelle
Journal:  JAMA Pediatr       Date:  2017-08-01       Impact factor: 16.193

Review 2.  Twenty years of take-home naloxone for the prevention of overdose deaths from heroin and other opioids-Conception and maturation.

Authors:  Rebecca McDonald; Nancy D Campbell; John Strang
Journal:  Drug Alcohol Depend       Date:  2017-05-25       Impact factor: 4.492

3.  Buprenorphine prescribing for opioid use disorder in medical practices: can office-based out-patient care address the opiate crisis in the United States?

Authors:  Taeho Greg Rhee; Robert A Rosenheck
Journal:  Addiction       Date:  2019-07-25       Impact factor: 6.526

4.  Association Between State Laws Facilitating Pharmacy Distribution of Naloxone and Risk of Fatal Overdose.

Authors:  Rahi Abouk; Rosalie Liccardo Pacula; David Powell
Journal:  JAMA Intern Med       Date:  2019-06-01       Impact factor: 21.873

5.  Opioid-overdose laws association with opioid use and overdose mortality.

Authors:  Chandler McClellan; Barrot H Lambdin; Mir M Ali; Ryan Mutter; Corey S Davis; Eliza Wheeler; Michael Pemberton; Alex H Kral
Journal:  Addict Behav       Date:  2018-03-19       Impact factor: 3.913

6.  Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in Texas, USA.

Authors:  Lucas G Hill; Lindsey J Loera; Kirk E Evoy; Mandy L Renfro; Sorina B Torrez; Claire M Zagorski; Joshua C Perez; Shaun M Jones; Kelly R Reveles
Journal:  Addiction       Date:  2020-11-22       Impact factor: 6.526

7.  Assessment of Racial and Ethnic Disparities in the Use of Medication to Treat Opioid Use Disorder Among Pregnant Women in Massachusetts.

Authors:  Davida M Schiff; Timothy Nielsen; Bettina B Hoeppner; Mishka Terplan; Helena Hansen; Dana Bernson; Hafsatou Diop; Monica Bharel; Elizabeth E Krans; Sabrina Selk; John F Kelly; Timothy E Wilens; Elsie M Taveras
Journal:  JAMA Netw Open       Date:  2020-05-01

8.  Association of Racial/Ethnic Segregation With Treatment Capacity for Opioid Use Disorder in Counties in the United States.

Authors:  William C Goedel; Aaron Shapiro; Magdalena Cerdá; Jennifer W Tsai; Scott E Hadland; Brandon D L Marshall
Journal:  JAMA Netw Open       Date:  2020-04-01

9.  Trends in the Use of Buprenorphine in US Emergency Departments, 2002-2017.

Authors:  Taeho Greg Rhee; Gail D'Onofrio; David A Fiellin
Journal:  JAMA Netw Open       Date:  2020-10-01

10.  Effectiveness of Scotland's National Naloxone Programme for reducing opioid-related deaths: a before (2006-10) versus after (2011-13) comparison.

Authors:  Sheila M Bird; Andrew McAuley; Samantha Perry; Carole Hunter
Journal:  Addiction       Date:  2016-02-04       Impact factor: 6.526
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.